KRN23
Phase 1Biologic
Kyowa Kirin Co., Ltd.KRN23 is one of 6 biologic programs targeting X-linked hypophosphatemic rickets. It is currently in Phase 1.
2
Indications
11
Total Trials
0
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in X-Linked Hypophosphatemia
#DrugCompanyPhaseTrials
1Rocaltrol
Alnylam PharmaceuticalsApproved
CRYSVITA
Kyowa Kirin Co., Ltd.Phase 2
Salmon Calcitonin
NovartisPreclinical
KRN23
Kyowa Kirin Co., Ltd.Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
X-linked hypophosphatemia4 trials
X-linked hypophosphatemic rickets3 trials
Efficacy2 trials
Pediatric1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for KRN23. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company